MX2015012201A - Formulaciones modificadas de liposomas de docetaxel. - Google Patents
Formulaciones modificadas de liposomas de docetaxel.Info
- Publication number
- MX2015012201A MX2015012201A MX2015012201A MX2015012201A MX2015012201A MX 2015012201 A MX2015012201 A MX 2015012201A MX 2015012201 A MX2015012201 A MX 2015012201A MX 2015012201 A MX2015012201 A MX 2015012201A MX 2015012201 A MX2015012201 A MX 2015012201A
- Authority
- MX
- Mexico
- Prior art keywords
- liposome formulations
- lipid
- docetaxel liposome
- taxane
- peg
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000004625 docetaxel anhydrous derivatives Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229940123237 Taxane Drugs 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930182558 Sterol Natural products 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 phosphatidylcholine lipid Chemical class 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779902P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/026483 WO2014160392A1 (en) | 2013-03-13 | 2014-03-13 | Modified docetaxel liposome formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012201A true MX2015012201A (es) | 2015-11-30 |
Family
ID=50686145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012201A MX2015012201A (es) | 2013-03-13 | 2014-03-13 | Formulaciones modificadas de liposomas de docetaxel. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140271822A1 (https=) |
| EP (1) | EP2968145A1 (https=) |
| JP (3) | JP6294456B2 (https=) |
| CN (1) | CN105188675A (https=) |
| BR (1) | BR112015022819A8 (https=) |
| CA (1) | CA2903255C (https=) |
| MX (1) | MX2015012201A (https=) |
| WO (1) | WO2014160392A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105188675A (zh) * | 2013-03-13 | 2015-12-23 | 马林克罗特有限公司 | 经修饰多西他赛脂质体制剂 |
| CN104622810B (zh) * | 2015-02-15 | 2018-06-08 | 中国药科大学 | 一种稳定型难溶性抗肿瘤药物脂质体及其制备方法 |
| US20160250177A1 (en) * | 2015-02-17 | 2016-09-01 | Mallinckrodt Llc | Modified docetaxel liposome formulations and uses thereof |
| CN107613962B (zh) | 2015-04-02 | 2021-02-09 | 纽约州立大学研究基金会 | 血清稳定组合物和用于光触发的材料释放的方法 |
| US20180344644A1 (en) * | 2015-09-21 | 2018-12-06 | Mallinckrodt Llc | Improved stability of liposome formulations and uses thereof |
| WO2017120586A1 (en) * | 2016-01-07 | 2017-07-13 | Western University Of Health Sciences | Formulations for treating bladder cancer |
| SG11201807148RA (en) * | 2016-03-16 | 2018-09-27 | Merrimack Pharmaceuticals Inc | Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions |
| CA3016383A1 (en) * | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc | Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions |
| US20190298681A1 (en) * | 2016-03-16 | 2019-10-03 | Merrimack Pharmaceuticals, Inc. | Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics |
| IL264842B (en) * | 2016-08-18 | 2022-08-01 | Troy Bremer | Delivery of urea to cells of the macula and retina using liposome constructs |
| CN107951861B (zh) * | 2016-10-17 | 2020-12-01 | 南京绿叶制药有限公司 | 一种脂质纳米粒膜材料组合物 |
| WO2018106980A1 (en) * | 2016-12-08 | 2018-06-14 | Mallinckrodt Llc | Liposomal elinafide formulations and uses thereof |
| US20190008987A1 (en) | 2017-07-07 | 2019-01-10 | Drexel University | Voltage-Activated Therapeutic, Diagnostic, And/Or Theranostic Constructs |
| CN110496103B (zh) * | 2018-05-18 | 2022-05-10 | 上海维洱生物医药科技有限公司 | 一种多西他赛棕榈酸酯脂质体及其制备方法 |
| JP7482487B2 (ja) * | 2018-09-13 | 2024-05-14 | タイワン リポソーム カンパニー リミテッド | 鎮静薬を含む徐放性医薬組成物およびその使用 |
| TWI767149B (zh) * | 2018-10-17 | 2022-06-11 | 台灣微脂體股份有限公司 | 含有免疫調節劑的緩釋藥物組合物及其用途 |
| US20220265679A1 (en) * | 2019-08-09 | 2022-08-25 | Tesorx Pharma, Llc | Proliposomal testosterone undecanoate formulations |
| CN110571005B (zh) * | 2019-09-27 | 2021-01-01 | 广西科技大学 | 一种固定化金属离子-磁性脂质体及其制备方法和应用 |
| CN111004195B (zh) * | 2019-12-03 | 2022-01-28 | 沈阳药科大学 | 卡巴他赛弱碱性衍生物及其制剂 |
| CN114588279B (zh) * | 2022-03-31 | 2023-10-20 | 重庆医科大学附属第二医院 | 一种多功能纳米分子探针及其制备方法和其作为视网膜母细胞瘤诊疗制剂的应用 |
| WO2025124498A1 (zh) * | 2023-12-13 | 2025-06-19 | 上海艾力斯医药科技股份有限公司 | 一种含氮杂环化合物的脂质体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994005282A1 (en) | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
| US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
| US6107332A (en) | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
| TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
| US6541508B2 (en) | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| EP1585504A4 (en) * | 2002-11-06 | 2009-07-15 | Azaya Therapeutics Inc | Protein stabilized liposomal formulations of pharmaceutical active ingredients |
| WO2005079185A2 (en) * | 2003-09-02 | 2005-09-01 | Board Of Regents, The University Of Texas System | Neutral liposome-encapsulated compounds and methods of making and using thereof |
| ATE401057T1 (de) * | 2004-10-08 | 2008-08-15 | Alza Corp | Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen |
| MX2007013200A (es) * | 2005-04-22 | 2008-03-24 | Johnson & Johnson | Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2. |
| CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
| EP3415151A1 (en) * | 2008-05-23 | 2018-12-19 | The University of British Columbia | Modified drugs for use in liposomal nanoparticles |
| CN102038641B (zh) * | 2009-10-26 | 2013-04-17 | 石药集团中奇制药技术（石家庄）有限公司 | 一种外层经亲水聚合物修饰的脂质体药物的制备方法 |
| US20120231066A1 (en) * | 2011-01-24 | 2012-09-13 | Henry John Smith | Multi-drug liposomes to treat tumors |
| JP2014503582A (ja) * | 2011-01-28 | 2014-02-13 | コーニンクレッカ フィリップス エヌ ヴェ | 親水性プロドラッグの局所放出用担体 |
| CN102188713A (zh) * | 2011-05-09 | 2011-09-21 | 中山大学 | 一种肝靶向药物组合物及其制备方法 |
| CN105188675A (zh) * | 2013-03-13 | 2015-12-23 | 马林克罗特有限公司 | 经修饰多西他赛脂质体制剂 |
-
2014
- 2014-03-13 CN CN201480026436.6A patent/CN105188675A/zh active Pending
- 2014-03-13 EP EP14722857.1A patent/EP2968145A1/en not_active Withdrawn
- 2014-03-13 US US14/208,324 patent/US20140271822A1/en not_active Abandoned
- 2014-03-13 JP JP2016502155A patent/JP6294456B2/ja not_active Expired - Fee Related
- 2014-03-13 BR BR112015022819A patent/BR112015022819A8/pt not_active IP Right Cessation
- 2014-03-13 CA CA2903255A patent/CA2903255C/en not_active Expired - Fee Related
- 2014-03-13 WO PCT/US2014/026483 patent/WO2014160392A1/en not_active Ceased
- 2014-03-13 MX MX2015012201A patent/MX2015012201A/es unknown
-
2017
- 2017-09-15 JP JP2017177620A patent/JP2017214433A/ja active Pending
-
2018
- 2018-09-18 JP JP2018173770A patent/JP2019006815A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015022819A8 (pt) | 2019-11-26 |
| EP2968145A1 (en) | 2016-01-20 |
| CN105188675A (zh) | 2015-12-23 |
| JP6294456B2 (ja) | 2018-03-14 |
| US20140271822A1 (en) | 2014-09-18 |
| CA2903255C (en) | 2018-08-28 |
| JP2019006815A (ja) | 2019-01-17 |
| JP2017214433A (ja) | 2017-12-07 |
| WO2014160392A1 (en) | 2014-10-02 |
| BR112015022819A2 (pt) | 2017-07-18 |
| CA2903255A1 (en) | 2014-10-02 |
| JP2016513655A (ja) | 2016-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015012201A (es) | Formulaciones modificadas de liposomas de docetaxel. | |
| MX2015012200A (es) | Composiciones de oxaliplatino en liposomas para la terapia contra el cancer. | |
| MX2015012199A (es) | Composiciones de cisplatino liposomal para la terapia contra el cancer. | |
| MX2014004960A (es) | Composiciones liposomales combinadas para terapia contra el cancer. | |
| MX2019003334A (es) | Composiciones liposomicas de inhibidores de proteasoma basadas en epoxicetona. | |
| MX2019005287A (es) | Lipidos cationicos para suministro de acido nucleico y su preparacion. | |
| IN2014DN05866A (https=) | ||
| SG10201906075VA (en) | Methods of treating cancer | |
| CY1115991T1 (el) | Φαρμακευτικη ψεκαζομενη συνθεση που περιλαμβανει ενα αναλογο της βιταμινης d προϊον και ενα κορτικοστεροειδες | |
| MX350258B (es) | Emulsiones cationicas de aceite en agua. | |
| EA201390203A1 (ru) | Способы получения тубулизинов | |
| TR201816986T4 (tr) | Terapötik ajan iletim formülasyonlarına yönelik lipitler. | |
| NZ718817A (en) | Lipid formulations for delivery of messenger rna | |
| IN2014DN00277A (https=) | ||
| BR112013000244A2 (pt) | lipossomas com lipídeos apresentando pka vantajoso para administração de rna | |
| NZ741291A (en) | Stabilizing camptothecin pharmaceutical compositions | |
| GB2507884A (en) | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current | |
| WO2013170012A3 (en) | Proliposomal testosterone formulations | |
| CA2882523C (en) | Lipid assemblies comprising anionic lysolipids and use thereof | |
| IN2014MN01571A (https=) | ||
| PL394082A1 (pl) | Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna | |
| IN2014CN03214A (https=) | ||
| WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
| BR112018068000A2 (pt) | composições de nanolipossomas de geração de docetaxel direcionados ao receptor a2 de efrina (epha2) | |
| WO2014167435A3 (en) | Liposomal pharmaceutical formulations for enhanced drug delivery |